The team will use a data-driven approach to identify novel drug combinations that are effective in tackling SARS-CoV-2, the causative agent of COVID-19. Despite the development of vaccines and drugs at an unprecedented pace to prevent and treat infection, there remains a huge gap in the development of antiviral therapies. Antiviral drugs are used specifically to treat viral infections by killing or preventing the growth of viruses. The research project will initially screen 138 drugs with known antiviral activity against SARS-CoV-2 to assess and identify combinations that enhance their antiviral potential. ‘Our goal is to identify repurposed drug combinations that are safe and effective against SARS-CoV-2 and suitable for use by the public.
